Novo Nordisk

Summary

In 1923 was created Novo Nordisk, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Bagsvu00e6rd. The company was established in Europe in Denmark.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Clinical Trials, Health Care. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight TransTech Pharma, Beta Bionics, IO Biotech.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2015. The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2014. This Novo Nordisk works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this Corporate Investor is 8 percentage points less often commits exit comparing to other companies.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Novo Nordisk, startups are often financed by Stafford Capital Partners, Sofinnova Partners, Gimv. The meaningful sponsors for the fund in investment in the same round are Yasuda Enterprise Development, Western Technology Investment, Sofinnova Partners. In the next rounds fund is usually obtained by RTW Investments LLC, OrbiMed, Novo Holdings.